AstraZeneca partners with Oxford University to develop a coronavirus vaccine

The biopharmaceutical giant, AstraZeneca, aims to develop a vaccine for coronavirus as early as possible, with the help of Oxford University’s Vaccine unit.

AstraZeneca is optimistic in coming up with a vaccine

To develop a coronavirus vaccine is urgent

These are the words of biopharmaceutical giant, AstraZeneca’s CEO, Pascal Soriot. The company has expressed its great interest in helping come up with a vaccine that will treat the damage of this epidemic.

In order to make this possible, Soriot made a deal with the University of Oxford to develop a vaccine against the coronavirus. If everything goes as plan, AstraZeneca will manufacture the vaccine and release it for limited consumption before the year ends.

As of now, the first human trial has already started just last week. Data gathered from these human trials will be available by the mid of June. And, if the vaccine proves to be effective, they will fast track its approval medically and legally to help level the field in the fight against COVID-19.

University of Oxford research team

AstraZeneca trusts the track record that the University of Oxford had in terms of research and medical advancement. It firmly believes that it has placed its trust on the right shoulders.

Currently, the vaccine team from Oxford is conducting their experiments at the Edward Jenner Institute for Vaccine Research. The team hopes to wield a positive outcome from its clinical trials, that will surely speed up the release of a medically proven vaccine against the coronavirus.

The firm will hold the right to only supply and manufacture the vaccine during the pandemic as agreed upon with the government and the Oxford group.